NO20045354L - Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser - Google Patents

Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser

Info

Publication number
NO20045354L
NO20045354L NO20045354A NO20045354A NO20045354L NO 20045354 L NO20045354 L NO 20045354L NO 20045354 A NO20045354 A NO 20045354A NO 20045354 A NO20045354 A NO 20045354A NO 20045354 L NO20045354 L NO 20045354L
Authority
NO
Norway
Prior art keywords
angiogenesis
metastasis
treatment
methods
tumor growth
Prior art date
Application number
NO20045354A
Other languages
English (en)
Norwegian (no)
Inventor
Leo E Otterbein
Augustine M K Choi
Original Assignee
Univ Pittsburg Of The Commonwe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburg Of The Commonwe filed Critical Univ Pittsburg Of The Commonwe
Publication of NO20045354L publication Critical patent/NO20045354L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20045354A 2002-06-05 2004-12-07 Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser NO20045354L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38656102P 2002-06-05 2002-06-05
PCT/US2003/017731 WO2003103585A2 (en) 2002-06-05 2003-06-05 Methods of treating angiogenesis, tumor growth, and metastasis

Publications (1)

Publication Number Publication Date
NO20045354L true NO20045354L (no) 2004-12-22

Family

ID=29736179

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045354A NO20045354L (no) 2002-06-05 2004-12-07 Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser

Country Status (14)

Country Link
US (1) US20040258772A1 (https=)
EP (1) EP1509237A4 (https=)
JP (1) JP2005532351A (https=)
CN (1) CN1674922A (https=)
AU (1) AU2003248621A1 (https=)
CA (1) CA2487413A1 (https=)
EA (1) EA200401622A1 (https=)
HR (1) HRP20041146A2 (https=)
MX (1) MXPA04012167A (https=)
NO (1) NO20045354L (https=)
PL (1) PL374375A1 (https=)
RS (1) RS105304A (https=)
UA (1) UA87438C2 (https=)
WO (1) WO2003103585A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1404811B1 (en) * 2001-06-21 2008-11-12 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7011854B2 (en) * 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
WO2003088981A1 (en) 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
EA200401365A1 (ru) 2002-04-15 2005-04-28 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Способы лечения илеуса
WO2003088748A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
EA200401525A1 (ru) 2002-05-17 2006-06-30 Йейл Юниверсити Способы лечения гепатита (варианты )
WO2004000368A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
DE10230165A1 (de) * 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
US20100158795A1 (en) * 2008-06-12 2010-06-24 Pulmonx Methods and systems for assessing lung function and delivering therapeutic agents
EP1558084A4 (en) * 2002-11-07 2008-04-30 Univ Pittsburgh TREATMENT OF HEMORRHAGIC SHOCK
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
CA2534415A1 (en) * 2003-08-04 2005-02-17 Northwick Park Institute For Medical Research Therapeutic delivery of carbon monoxide
CN100475275C (zh) * 2004-01-05 2009-04-08 董永华 肿瘤血管栓塞剂及其储存和释放装置
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
JP5552262B2 (ja) * 2009-05-13 2014-07-16 フクダ電子株式会社 肺疾患の治療に用いられる気体製剤
CN109925318A (zh) * 2011-01-14 2019-06-25 洛杉矶儿童医院 用于治疗包括镰状细胞疾病的疾病的一氧化碳溶液
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
WO2013022946A1 (en) 2011-08-09 2013-02-14 Beth Israel Deaconess Medical Center, Inc. Methods of treating dna damage
WO2018225785A1 (ja) * 2017-06-06 2018-12-13 株式会社Ａｔｏｍｉｓ ワクチン組成物
WO2021105900A1 (en) * 2019-11-25 2021-06-03 Beyond Air, Inc. System and method for delivery of gas to a tissue
US20230346831A1 (en) * 2020-07-16 2023-11-02 Cornell University Methods for treating metastatic cancer using low dose carbon monoxide

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5449665A (en) * 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) * 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) * 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) * 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) * 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
AU5938696A (en) * 1995-06-30 1997-02-05 Zymogenetics Inc. 4-(2-(n-2-carboxamidoindole)aminoethyl)-benzenesulfonamides or sulfonylureas as pdgf antagonists
ATE331505T1 (de) * 1996-04-05 2006-07-15 Gen Hospital Corp Behandlung einer hämoglobinstörung
US6069132A (en) * 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
EP1064277B1 (en) * 1998-03-16 2005-06-15 Celgene Corporation 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
US6203991B1 (en) * 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
CA2442457A1 (en) * 2001-03-30 2002-10-10 Roland Buelow Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1395241B9 (en) * 2001-05-25 2005-06-15 Medtronic, Inc. Implantable medical device with controllable gaseous agent release system
EP1404811B1 (en) * 2001-06-21 2008-11-12 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
US7069026B2 (en) * 2001-06-28 2006-06-27 Nokia Corporation Geographic area assisted system selection for mobile stations
US7011854B2 (en) * 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
SG148850A1 (en) * 2002-02-13 2009-01-29 Beth Israel Hospital Methods of treating vascular disease
WO2003088981A1 (en) * 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
EA200401365A1 (ru) * 2002-04-15 2005-04-28 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Способы лечения илеуса
EA200401525A1 (ru) * 2002-05-17 2006-06-30 Йейл Юниверсити Способы лечения гепатита (варианты )
WO2004000368A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
EP1558084A4 (en) * 2002-11-07 2008-04-30 Univ Pittsburgh TREATMENT OF HEMORRHAGIC SHOCK

Also Published As

Publication number Publication date
CA2487413A1 (en) 2003-12-18
EA200401622A1 (ru) 2005-06-30
AU2003248621A1 (en) 2003-12-22
PL374375A1 (en) 2005-10-17
MXPA04012167A (es) 2005-09-21
RS105304A (sr) 2007-02-05
HRP20041146A2 (en) 2005-06-30
CN1674922A (zh) 2005-09-28
UA87438C2 (ru) 2009-07-27
JP2005532351A (ja) 2005-10-27
US20040258772A1 (en) 2004-12-23
EP1509237A2 (en) 2005-03-02
WO2003103585A2 (en) 2003-12-18
WO2003103585A3 (en) 2004-08-26
EP1509237A4 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
NO20045056L (no) Fremgangsmater for behandling av hepatitt
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
EA200401365A1 (ru) Способы лечения илеуса
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
NO20060307L (no) Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
DE50310516D1 (de) Fredericamycin-derivate
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
NO20050607L (no) Fremgangsmate og innretning for tildeling av CO
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
MY169308A (en) Treatment of tnf? related disorders
WO2004065423A3 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
SE0302312D0 (sv) Peptide-based passive immunization therapy for treatment of atherosclerosis
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft
NO20064753L (no) Kombinasjonsterapi
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application